Woodline Partners LP Mirati Therapeutics, Inc. Transaction History

Woodline Partners LP

$9.97 Billion
Q2 2024

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$27.8 - $45.35 $2.64 Million - $4.31 Million	-95,109 Reduced 25.48%	278,223 $12.1 Million
Q2 2023 Aug 14, 2023	BUY	$36.13 - $49.49 $3.87 Million - $5.31 Million	107,232 Added 40.3%	373,332 $13.5 Million
Q1 2023 May 15, 2023	SELL	$36.54 - $54.26 $13.5 Million - $20.1 Million	-370,617 Reduced 58.21%	266,100 $9.89 Million
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $17.1 Million - $40.8 Million	414,209 Added 186.15%	636,717 $28.8 Million
Q3 2022 Nov 14, 2022	SELL	$59.5 - $86.7 $4.23 Million - $6.16 Million	-71,059 Reduced 24.21%	222,508 $15.5 Million
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $6.56 Million - $14.9 Million	167,519 Added 132.9%	293,567 $19.7 Million
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $87,647 - $174,521	1,156 Added 0.93%	126,048 $10.4 Million
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $1.55 Million - $2.24 Million	11,749 Added 10.38%	124,892 $18.3 Million
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $2.49 Million - $3.35 Million	18,867 Added 20.01%	113,143 $20 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $9.1 Million - $11.4 Million	63,173 Added 203.11%	94,276 $15.2 Million
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $4.94 Million - $6.89 Million	31,103 New	31,103 $5.33 Million
Q3 2020 Nov 16, 2020	SELL	$113.26 - $167.27 $5.86 Million - $8.65 Million	-51,742 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$72.01 - $120.39 $3.54 Million - $5.92 Million	-49,211 Reduced 48.75%	51,742 $5.91 Million
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $7.04 Million - $11.7 Million	100,953 New	100,953 $7.76 Million

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Account